Overview |
bsm-54043r-100ul |
CD39 (3G4) Monoclonal Antibody |
WB, IHC-P |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
Human CD39 aa 300-450 |
Monoclonal |
3G4 |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Store for 1 year at -20°C from date of shipment. Store for 1 year at -20°C from date of shipment. |
Target |
953 |
P49961 |
Ectonucleoside triphosphate diphosphohydrolase 1, Ecto-ATP diphosphohydrolase 1, Ecto-apyrase, Lymphoid cell activation antigen, NTPDase 1, Ecto-ATPDase 1, Ecto-ATPase 1, CD39, ENTPD1 |
CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that acts as an extracellular nucleotide-hydrolyzing enzyme. CD39 inhibits ADP-induced platelet aggregation by hydrolyzing ADP to AMP and ultimately generating adenosine. Intracellular CD39 undergoes glycosylation at 6 N-glycosylation sites and translocates to the membrane in order to be an active enzyme. Alternative splicing gives rise to three CD39 isoforms, vascular, placenta I and placenta II. The placenta I isoform differs at the amino terminus whereas the placenta II isoform is missing amino acids 300-510 at the C-terminus. CD39 is expressed in vascular tissues including placenta, lung, skeletal muscle and kidney, as well as endothelium, smooth muscle, cardiac cells, lymphocytes (such as activated B cells) activated NK cells, macrophages, dendridic cells and platelets. CD39 may be used as an anti-thrombic agent for pre-treating patients at risk for coronary artery occlusion and thrombic stroke. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |